CA
AUPH icon

Cetera Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Cetera Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		$301K Buy
60,139
+9,547
+19% +$64.8K ﹤0.01% 1937
2023
Q4 		$455K Buy
50,592
+2,400
+5% +$19.8K 0.01% 1187
2023
Q3 		$374K Buy
48,192
+2,828
+6% +$27.7K 0.01% 1212
2023
Q2 		$439K Buy
45,364
+1,065
+2% +$11.1K 0.01% 1129
2023
Q1 		$486K Buy
44,299
+8,999
+25% +$79.3K 0.01% 1036
2022
Q4 		$152K Hold
35,300
– – ﹤0.01% 1474
2022
Q3 		$265K Buy
35,300
+300
+0.9% +$2.6K 0.01% 1025
2022
Q2 		$352K Buy
35,000
+3,251
+10% +$36.3K 0.01% 983
2022
Q1 		$393K Buy
31,749
+4,550
+17% +$70.3K 0.01% 983
2021
Q4 		$622K Sell
27,199
-1,069
-4% -$25.3K 0.01% 797
2021
Q3 		$626K Buy
28,268
+16,163
+134% +$256K 0.01% 792
2021
Q2 		$157K Buy
+12,105
New +$154K ﹤0.01% 1268

Other funds holding AUPH

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Cetera Advisors's AUPH Position: Q1 2024 in Review

Cetera Advisors increased its Aurinia Pharmaceuticals (AUPH) stake by 19% in Q1 2024, buying an estimated $64.8K and bringing the position to 60,139 shares worth $301K. The position accounts for ﹤0.01% of the portfolio, ranked #1937.

Cetera Advisors first reported a position in AUPH in Q2 2021 and has held it in 12 quarters since. The position peaked at $626K in Q3 2021. 179 funds tracked by Wall St. Rank hold AUPH as of Q1 2024.

  • Cetera Advisors held 60,139 shares of Aurinia Pharmaceuticals worth $301K as of Q1 2024.
  • Cetera Advisors bought 9,547 Aurinia Pharmaceuticals shares in Q1 2024, an estimated $64.8K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Cetera Advisors's portfolio in Q1 2024, its #1937 holding.
  • Cetera Advisors first reported a position in Aurinia Pharmaceuticals in Q2 2021 and has held it in 12 quarters since.
  • Cetera Advisors's Aurinia Pharmaceuticals position peaked at $626K in Q3 2021.
  • 179 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2024.

Based on Cetera Advisors's 13F filing for Q1 2024, filed 15 May 2024.